Vincent Medical Holdings Limited (“Vincent Medical” or together with its subsidiaries, the “Group”, stock code: 1612), is pleased to announce its first unaudited interim results for the six months ended 30 June 2016 (the “Period”) since its successful listing on the Main Board of the Stock Exchange of Hong Kong Limited (“HKSE”) on 13 July 2016.
During the Period, Vincent Medical remained fully committed to growth through continuously developing innovative products that can address patients’ needs and have potential for future commercialisation to diversify its OBM product portfolio, in particular focusing on the respiratory and orthopedic and rehabilitation categories. The Group recorded revenue of approximately HK$237.9 million, representing a growth of approximately 6.4% as compared to the corresponding period in 2015. Gross profit rose by 14.9% to approximately HK$77.9 million, while gross profit margin for the Period was 32.7%. Excluding the one-off listing-related expenses and the share based compensation expenses of approximately HK$17.3 million, the profit attributable to owners of the Company based on the underlying net profit for the Period was approximately HK$29.4 million, representing an increase of approximately 33.6% as compared to that for the corresponding period in 2015. Basic earnings per share was 2.53 HK cents.